Aclaris Therapeutics, Inc. (ACRS) |
|
14.13 -0.2 (-1.4%)
|
02-03 15:38 |
|
Open: |
14.81 |
Pre. Close: |
14.33 |
|
High:
|
15.22 |
Low:
|
13.9 |
|
Volume:
|
1,673,692 |
Market Cap:
|
942(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:15:04 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 19.65  One year: 21.65 |
| Support: |
Support1: 14.06 Support2: 11.69 |
| Resistance: |
Resistance1: 16.82 Resistance2: 18.54 |
| Pivot: |
16.68 |
| Moving Average: |
MA(5): 15.94 MA(20): 16.72
MA(100): 15.94 MA(250): 15.4  |
| MACD: |
MACD(12,26): -0.2 Signal(9): 0.1 |
| Stochastic oscillator: |
%K(14,3): 13.8 %D(3): 27.4 |
| RSI: |
RSI(14): 33.5 |
| 52-week: |
High: 18.95 Low: 9.84 |
| Average Vol(K): |
3-Month: 419 (K) 10-Days: 730 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ ACRS ] has closed below the lower bollinger band by 10.4%. Bollinger Bands are 29.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
17.62 - 17.71 |
17.71 - 17.79 |
|
Low:
|
14.02 - 14.11 |
14.11 - 14.2 |
|
Close:
|
14.16 - 14.31 |
14.31 - 14.45 |
|
Company Description |
|
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania. |
Headline News |
Thu, 02 Feb 2023
SG Americas Securities LLC Invests $214000 in Aclaris ... - MarketBeat
Tue, 31 Jan 2023
BlackRock Increases Position in Aclaris Therapeutics (ACRS) - Nasdaq
Mon, 30 Jan 2023
Do Traders Think Aclaris Therapeutics Inc (ACRS) Can Keep Climbing Monday? - InvestorsObserver
Mon, 30 Jan 2023
Stock Upgrades: Viatris Shows Rising Relative Strength | Investor's ... - Investor's Business Daily
Wed, 25 Jan 2023
Is Aclaris Therapeutics Inc (ACRS) a Leader in the Diagnostics & Research Industry? - InvestorsObserver
Tue, 17 Jan 2023
UK government urged to honour pledge to Afghan refugees’ families - The Guardian
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Diagnostics & Research |
| Shares Out. |
0 (M) |
| Shares Float |
67 (M) |
|
% Held by Insiders
|
4.376e+007 (%) |
|
% Held by Institutions
|
3 (%) |
|
Shares Short
|
2,660 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-8.217e+007 |
|
EPS Est Next Qtl
|
-1.13 |
|
EPS Est This Year
|
-3.1 |
|
EPS Est Next Year
|
-3.18 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-356.9 |
|
Return on Assets (ttm)
|
-19.8 |
|
Return on Equity (ttm)
|
-37.7 |
|
Qtrly Rev. Growth
|
1 |
|
Gross Profit (p.s.)
|
80 |
|
Sales Per Share
|
4.05172e+007 |
|
EBITDA (p.s.)
|
-7.20172e+007 |
|
Qtrly Earnings Growth
|
-1.4 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-66 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
-0.2 |
|
Price to Book value
|
0 |
|
Price to Sales
|
0 |
|
Price to Cash Flow
|
2.47 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
2.84e+006 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
